Bristol-Myers Squibb CoBMY:NYQ

58.98
4.82 / 8.90%
28.34m
11.01%
0.3867
Close in USDToday's changeShares traded1 year changeBeta
Data delayed at least 15 minutes, as of Oct 30 2014 20:01 GMT.

Summary

Bristol-Myers Squibb Co (BMY:NYQ) set a new 52-week high during Thursday's trading session when it reached 59.03. Over this period, the share price is up 12.39%.

52-week range
Today
46.30
Jun 05 2014
59.03
Oct 30 2014
Markit short selling activity
Low
Medium
High
Open55.72
Day high--
Day low--
Bid57.01
Offer60.09
Previous close58.98
Average volume9.74m
Shares outstanding1.66bn
Free float1.64bn
P/E (TTM)36.23
Market cap97.83bn USD
EPS (TTM)1.63 USD
Annual div (TTM)1.44 USD
Annual div yield (TTM)2.44%
Div ex-dateOct 01 2014
Div pay-dateNov 03 2014
Data delayed at least 15 minutes, as of Oct 30 2014 20:01 GMT.

Comparative analysis

Past 90 days
1 week1 month6 months1 year5 years
Bristol-Myers Squibb Co+12.34%+15.24%+19.10%+11.01%+170.55%
S&P 500 INDEX+2.25%+1.13%+5.89%+13.12%+92.50%
USA/HEALTH CARE+2.59%+4.62%+13.49%+21.40%--
USA/PHARMACEUTICALS+2.70%+2.30%+5.92%+17.20%--
Data delayed at least 15 minutes, as of Oct 30 2014 20:01 GMT.
© Thomson Reuters Click for restrictions.

All markets data located on FT.com is subject to the FT Terms & Conditions.

All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.

Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.

Markit Short Selling Activity © Markit. All rights reserved.
Although Markit has made every effort to ensure this data is correct, nevertheless no guarantee is given to the accuracy or completeness. Any opinions or estimates expressed herein are those of Markit on the date of preparation and are subject to change without notice; however no such opinions or estimates constitute legal, investment or other advice. You must therefore seek independent legal, investment or other appropriate advice from a suitably qualified and/or authorised and regulated advisor prior to making any legal, investment or other decision. This is intended for information purposes only and is not intended as an offer or recommendation to buy, sell or otherwise deal in securities.